FDA hits Xspray Pharma with Complete Response Letter for its leukemia candidate
The CRL relates to Good Manufacturing Practice observations at third-party manufacturer NerPharMa, and a request for additional commercial-scale consecutive batch data.
Read the full article on the original site.
Read Full Article